Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 3.03B |
| Revenue (ttm) | 34.03M |
| Net Income (ttm) | -58.41M |
| Shares Out | 51.04M |
| EPS (ttm) | -1.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,169,960 |
| Open | 64.20 |
| Previous Close | 64.90 |
| Day's Range | 58.13 - 64.20 |
| 52-Week Range | 27.65 - 91.92 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 78.43 (+24.6%) |
| Est. Earnings Date | Nov 5, 2021 |
About KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the...
Financial Performance
In 2020, KYMR's revenue was $34.03 million, an increase of 1,059.99% compared to the previous year's $2.93 million. Losses were -$45.59 million, 10.5% more than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is 78.43, which is an increase of 24.59% from the latest price.
News
Kymera Therapeutics to Present at Upcoming September Investor Conferences
WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...
Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update
Positive interim results from Single Ascending Dose portion of Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 demonstrated degrader proof-of-mechanism
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and W...
Data demonstrate Kymera's ability to degrade mutant and wild-type STAT3, a traditionally “undruggable” target, and the broad therapeutic potential for the treatment of peripheral T-cell lymphoma subtype...
Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' O...
WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...
Kymera Prices $223M Equity Offering At $47/Share
Kymera Therapeutics Inc (NASDAQ: KYMR) has priced its upsized underwritten public offering of 4.7 million shares at $47.00 per share, representing a discount of 3% from the last close price of $48.5 on ...
Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...
Kymera Therapeutics Seeks To Raise Capital Via 4M Shares Equity Offering To Fund Oncology Franchises
Kymera Therapeutics Inc (NASDAQ: KYMR) commenced an underwritten public offering of 4 million shares of common stock. Underwriters can purchase up to an additional 600k shares.
Kymera Therapeutics Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...
Kymera's KT-474 Achieved Sustained IRAK4 Reduction After Single Dose In Healthy Volunteers
Kymera Therapeutics Inc (NASDAQ: KYMR) has announced interim results from the Single Ascending Dose (SAD) portion of the Phase 1 trial of KT-474 in healthy volunteers. KT-474 has exceeded the Phase 1 ta...
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrati...
KT-474 has achieved and exceeded Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial dosed to date, with 90% median degradation at the 300 mg dose
Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer
WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...
Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity
Kymera Therapeutics Inc (NASDAQ: KYMR) has announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination with other anticancer agents. The data were...
Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
WATERTOWN, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...
Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase
Novel E3 ligase identified by Kymera's Whole-Body Atlas is expressed in selected tissues while broadly expressed in cancer cells
Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting
New in vivo data demonstrate the broad anti-inflammatory activity of KT-474 and its superiority compared to a clinically active small molecule IRAK4 kinase inhibitor in preclinical immune-inflammatory m...
Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update
Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 initiated in February; on track to present human proof-of-biology data in 4Q 2021
Kymera Therapeutics to Present at Upcoming May Investor Conferences
WATERTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molec...
Kymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degra...
Data demonstrate KT-474's superiority compared to a clinically active small molecule IRAK4 kinase inhibitor across a wide variety of immune-inflammatory preclinical models Data demonstrate KT-474's supe...
Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company
WATERTOWN, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...
Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IR...
KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1 Interferon pathways resulting in superior antitumor activity in MYD88-mutant DLBCL models co...
Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at...
WATERTOWN, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...
Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors
WATERTOWN, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...
Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader...
KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development
Kymera Therapeutics to Present at Upcoming March Investor Conferences
WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein d...
Kymera Therapeutics Strengthens Leadership with Key Appointments and Promotions
WATERTOWN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein d...